Stereotaxis Reports 39% Q4 Revenue Growth, Faces Challenges

Stereotaxis (STXS) reported a 39% increase in fourth-quarter revenue, reaching $6.3 million, although it experienced a slight decline in full-year system revenue. The company's Q4 earnings call highlighted a mix of optimism and caution, with notable advancements in FDA submissions and strategic acquisitions aimed at enhancing its market position. However, Stereotaxis faced challenges including increased operating losses and ongoing commercial uncertainties, particularly in China. Looking ahead, the company anticipates double-digit revenue growth for 2025, driven by an expanded catheter portfolio and expectations of improved recurring revenue. Stereotaxis generated positive cash flow in Q4 and ended the year with a strong balance sheet, positioning it to advance its product ecosystem. CEO David Fischel emphasized that the company is on track to transform its product offerings and achieve significant commercial growth in the near future.